SIRT1 and Hepatic fibrosis: Interestingly, we tried to attain the same goal by administering the SIRT1 agonist SRT2104 (100 mg/kg, 1 week) to mice in our CCl4-induced liver fibrosis model, without achieving recovery in SIRT1 activity (data not shown), and, accordingly, liver inflammation or damage was not modified by SRT2104 treatment.